Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GlaxoSmithKline PLC Regulatory Filings 2020

Apr 1, 2020

5262_rns_2020-04-01_95cc6a9f-3ab7-4df3-81cf-7953b83a876a.html

Regulatory Filings

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4084I

GlaxoSmithKline PLC

01 April 2020

GlaxoSmithKline plc

Total Voting Rights and Capital

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following:

The Company's issued share capital as at 31 March 2020 consisted of 5,384,749,852 shares of 25 pence each ('Ordinary Shares'), of which 367,705,950 Ordinary Shares were held in Treasury.

Therefore, the total number of voting rights in the Company is 5,017,043,902. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

V A Whyte

Company Secretary

1 April 2020

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

TVRUPUUGCUPUGUG